Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia
- 87 Downloads
Therapy for chronic lymphocytic leukemia has improved dramatically over the past 20 years. Traditional therapy with oral chlorambucil led to complete responses in less than 5% of treated patients, in marked contrast to modern regimens, which can reliably produce complete responses in over 50% of patients. This remarkable improvement is attributable to the use of purine analogue-based treatment as well as monoclonal antibodies. Novel combinations of these agents have emerged as effective new therapies for previously untreated patients. Clinical studies indicate that such combinations can induce higher response rates (including complete responses) than single-agent therapy. Those patients who achieve a complete response have superior progression-free survival compared with those who achieve only a partial response. Though not yet demonstrated in a prospective randomized trial, treatment approaches aimed at achieving high-quality responses may one day improve survival for patients with chronic lymphocytic leukemia. However, many challenges remain, such as finding less toxic and equally efficacious regimens for older patients, who remain the majority of the population with this disease.
KeywordsChronic lymphocytic leukemia Frontline treatment
Dr. Lamanna has been a consultant for Celgene and has received research support from Hospira, Celgene, and Biogen-Idec.
Papers of particular interest, published recently, have been highlighted as: • Of Importance •• Of Major Importance
- 14.Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12): 5446–5456.CrossRefPubMedGoogle Scholar
- 19.Del Principe MI, Del Poeta G, Buccisano F, et al.: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006, 108:843–861.Google Scholar
- 22.National Cancer Institute: Early or delayed fludarabine and rituximab in treating patients with previously untreated chronic lymphocytic leukemia [clinical trial]. Available at: http://www.clinicaltrials.gov/ct2/results?term=NCT00513747. Accessed November 13, 2009.
- 34.• Lamanna N, Weiss MA, Maslak PG, et al.: Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27:491–497. This study demonstrated that PCR negativity confers a 90% likelihood of a 5-year or greater duration of complete response.CrossRefPubMedGoogle Scholar
- 35.Byrd JC, Peterson BL, Morrison VA, et al.: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101:6–14.CrossRefPubMedGoogle Scholar
- 36.Byrd JC, Rai K, Peterson BL, et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49–53.CrossRefPubMedGoogle Scholar
- 37.Hallek M, Fingerle-Rowson G, Fink AM, et al.: Immunochemotherapy with fludarabine, cyclophosphamide, and rituximab versus fludarabine and cyclophosphamide improves response rates and progression free survival of previously untreated patients with advanced chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 325.Google Scholar
- 39.Robak T, Blonski JZ, Gora-Tybor J, et al.: Comparison of cladribine plus cyclophosphamide or fludarabine plus cyclophosphamide in different age groups in previously untreated patients with chronic lymphocytic leukemia (PALG-CLL3 study) [abstract 0407]. Haematologica 2008, 93(suppl 1):162.Google Scholar
- 43.• Shanafelt TD, Lin T, Geyer SM, et al.: Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007, 109:2291–2298. This study confirmed that the “PCR” regimen is active and tolerable in patients older than 65 years of age.CrossRefPubMedGoogle Scholar
- 49.Rai K, Byrd J, Peterson BL, Larson RA: A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901 [abstract]. Blood 2002, 100:205a.Google Scholar
- 51.Morrison VA, Peterson FL, Rai KR, et al.: Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia receiving fludarabine-based therapy: A comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 756.Google Scholar
- 52.Lin TS, Donohue KA, Lucas MS, et al.: Consolidation therapy with subcutaneous alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab induction therapy: Interim safety analysis of CALGB 10101 [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 755.Google Scholar
- 53.Chen C, Paul H, Xu W, et al.: A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 44.Google Scholar
- 54.Ferrajoli A, O’Brien S, Wierda W, et al.: Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:abstract 45.Google Scholar
- 55.Surveillance, Epidemiology, and End Results Program: Median age of cancer patients at diagnosis, 2002–2006 by primary cancer site, race and sex. Bethesda, MD: National Cancer Institute; 2006. Available at http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.11_2pgs.pdf. Accessed October 19, 2009.
- 56.Ferrajoli A, O’Brien S, Wierda W, et al.: Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005, 46(suppl 1):S86.Google Scholar
- 57.• Eichhorst BF, Busch R, Stilgenbauer S, et al.: First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382–3391. This important paper confirms that fludarabine does not result in a major clinical benefit in patients older than 65 years of age, versus treatment with chlorambucil.CrossRefPubMedGoogle Scholar